0IL8 Stock Chart & Stats
$7.96
-$0.27(-3.62%)
At close: 4:00 PM EDT
$7.96
-$0.27(-3.62%)
Day’s Range― - ―
52-Week Range$5.72 - $11.56
Previous CloseN/A
Volume211.00
Average Volume (3M)646.00
Market Cap
$24.78M
Enterprise Value-$38.76M
Total Cash (Recent Filing)$91.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)0.1
Beta0.77
Next Earnings
Nov 09, 2026EPS Estimate
-3.55Next Dividend Ex-DateN/A
Dividend Yield0.02%
Share Statistics
EPS (TTM)58.19
Shares Outstanding4,049,124
10 Day Avg. Volume1,132
30 Day Avg. Volume646
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap-1.56
Enterprise Value/Revenue-8.39
Enterprise Value/Gross Profit-46.25
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$38.50Price Target Upside383.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-9.65
Revenue Forecast (FY)$6.76M
Bulls Say, Bears Say
Bulls Say
Differentiated Oncology PlatformThe non-PSMA approach and linked companion imaging agent could give Kyntra a differentiated position in prostate cancer. A biomarker-supported strategy may improve patient selection and create a more focused commercial niche if larger trials confirm the early signal.
Advancing Clinical PipelineTwo programs are moving toward important development milestones, providing several potential value-creation paths beyond a single asset. Phase II enrollment and a finalized Phase III design demonstrate operational progress that can support future partnering or commercialization if efficacy and safety hold.
Reduced Future Financing ObligationsLower contractual payments and eliminated true-up obligations should reduce the burden on future royalties and improve financial flexibility. Retaining royalties after the capped obligation ends can also preserve more long-term economics from the associated commercial products.
Bears Say
Contracting Revenue And Weak Operating PerformanceShrinking revenue alongside substantial operating losses indicates that the current business is not yet generating durable operating earnings. The sharp margin deterioration increases dependence on pipeline milestones, licensing income, or external financing to support ongoing development.
Cash Burn And Negative EquityPersistent cash consumption reduces the capital available for clinical execution and makes future funding needs more likely. Negative shareholders’ equity also signals a weak capital cushion, limiting resilience if development costs rise or expected operating inflows fail to materialize.
Nasdaq Delisting UncertaintyThe unresolved listing issue creates an ongoing corporate and financing risk rather than a temporary trading fluctuation. Failure to regain compliance could reduce market access, complicate capital raising, and distract management while the company advances its clinical programs.
Kyntra Bio News
0IL8 FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest share price was $5.72 and its highest was $11.56 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $24.78M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Nov 09, 2026 which is in 26 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Aug 13, 2026. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of -$3.184 by $6.144.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 0.02%. See more information on Kyntra Bio dividends here
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.55.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,049,124 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of $2.96 in its last earnings report, beating expectations of -$3.184. Following the earnings report the stock price went down -1.367%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in GB:0IL8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
0IL8 Company Deck
0IL8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.View all GB:0IL8 earnings summaries0IL8 Stock 12 Month Forecast
Average Price Target
$38.50
▲(383.67% Upside)
Technical Analysis
Grace Therapeutics
―
―
OnKure Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―